Pharmaceutical composition comprising compound SYN045, preparation and preparation method thereof

Through the mannitol and corn starch filler composition, the dissolution and stability of SYN045 drug are solved, high dissolution and low impurity content are achieved, the safety and effectiveness of the drug are ensured, and the preparation process is simplified.

CN118903146AActive Publication Date: 2024-11-08SHIJIAZHUANG NO 4 PHARMACEUTICAL CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410982244.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-08
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

The SYN045 drug has poor dissolution and strong hydrophobicity, which affects the efficacy of the drug, and has poor stability of the preparation, resulting in low content uniformity, impurities problems, and threatens the safety of the drug.

Method used

The SYN045 pharmaceutical composition is prepared by a wet process using a fixed ratio of mannitol and corn starch filler composition, which improves dissolution and stability, reduces impurities and ensures uniformity of drug content.

Benefits of technology

The high dissolution, low impurity content and high bioavailability of SYN045 drugs are achieved, ensuring the safety and effectiveness of the drugs, simplifying the preparation process, and meeting the content uniformity requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004956419110000051
    Figure BDA0004956419110000051
  • Figure BDA0004956419110000061
    Figure BDA0004956419110000061
  • Figure BDA0004956419110000062
    Figure BDA0004956419110000062
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and particularly provides a pharmaceutical composition containing a compound SYN045 and a preparation method of the pharmaceutical composition. The mannitol and the corn starch in a fixed ratio are used as filling agents, so that the product quality problems of poor preparation content uniformity and the like caused by unstable active ingredients, easiness in degradation and difficulty in uniformly mixing raw materials and auxiliary materials in a wet process are solved, impurities are effectively reduced while effective dissolution of the active ingredients is realized, and the product quality is improved. Therefore, the effectiveness and safety of the medicine are effectively guaranteed, the content uniformity of the preparation product is high, the purpose of meeting the content uniformity requirement through a simple mixing mode is achieved through the combination, and the preparation process is simplified.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a pharmaceutical composition comprising the compound SYN045, a preparation and a preparation method thereof. Background Art

[0002] Pulmonary hypertension is a malignant disease characterized by increased pulmonary vascular resistance and pulmonary artery pressure caused by pulmonary artery lesions. In severe cases, it can lead to right heart failure or even death. The latest data show that the incidence and prevalence of pulmonary hypertension in adults are 0-6 cases and 48-55 cases per million people, respectively. Due to its rapid progression, high mortality and disability rates, it is regarded as a "malignant tumor" in the cardiovascular field.

[0003] SYN045, whose chemical name is 6-((5,6-diphenyl-1,2,4-triazine-3-yl)(isopropyl)amino)-N-(methylsulfonyl)hexanamide, is a small molecule compound with a new structure. SYN045 is a prostacyclin receptor (PGI2) targeted drug. Preclinical studies have shown that it has a prominent antihypertensive effect and can significantly improve the symptoms related to pulmonary hypertension in rats with pulmonary hypertension model. At the same time, it improves the rats' tolerance dose and survival rate, and has a high safety.

[0004] The SYN045 compound has poor solubility and strong hydrophobicity, and is insoluble in water, which may affect the dissolution, absorption and bioavailability of the drug after administration, thereby restricting its efficacy. In addition, due to the strong efficacy of SYN045, the specifications of the clinical development preparation are small, and there is a problem of poor content uniformity; at the same time, during the prescription research of the new compound SYN045, it was found that its preparation had poor stability and was prone to produce impurities, resulting in a decrease in drug content, which to a certain extent posed a threat to the safety of the drug.

[0005] In view of the excellent activity of SYN045, there is an urgent need to develop a SYN045 pharmaceutical composition with good in vitro dissolution, high content uniformity, and few impurities to ensure the safety and effectiveness of clinical medication. Summary of the invention

[0006] The purpose of the present invention is to provide a pharmaceutical composition of compound SYN045 with good dissolution, high content uniformity and low impurity content and a preparation method thereof in view of the defects of the prior art. The present invention solves the product quality problem of the wet process by using a fixed ratio of mannitol and corn starch filler composition, realizes effective dissolution of active ingredients while reducing the generation of impurities, ensures drug effectiveness and safety, and at the same time, the content uniformity of the preparation product is high. This combination realizes that the content uniformity requirements can be met without a too complicated mixing method, simplifying the preparation process.

[0007] To achieve the purpose of the present invention, the following technical solutions are adopted:

[0008] An object of the present invention is to provide a pharmaceutical composition comprising a compound SYN045, wherein the composition comprises the following components in percentage by weight: 0.06%-0.8% of the compound SYN045, 83%-88% of a filler, 2.7%-3.4% of a binder, 9.0%-11.2% of a disintegrant and 0.9%-1.2% of a lubricant; wherein the filler is a mixture of mannitol and corn starch; and the mass ratio of mannitol to corn starch is 14:90-121.

[0009] Furthermore, the binder is hydroxypropyl cellulose.

[0010] Furthermore, the disintegrant is low-substituted hydroxypropyl cellulose.

[0011] Furthermore, the lubricant is one or both of magnesium stearate or talc.

[0012] Furthermore, the pharmaceutical composition comprising the compound SYN045 can be prepared into an oral solid preparation.

[0013] The second object of the present invention is to provide a pharmaceutical preparation, which comprises the above-mentioned pharmaceutical composition comprising the compound SYN045.

[0014] Furthermore, the dosage form of the pharmaceutical preparation is tablets, capsules, granules or dry suspensions.

[0015] Furthermore, the tablet may be a common tablet or a coated tablet.

[0016] Furthermore, the pharmaceutical preparation may also contain other excipients.

[0017] Furthermore, the coated tablet may further comprise a coating agent.

[0018] Furthermore, the coated tablet comprises the following components in percentage by mass: compound SYN045 0.08%-0.7%, filler 81%-85%, binder 2.6%-3.3%, disintegrant 8.8%-10.9%, lubricant 0.88%-1.09% and coating agent 2.6%-3.3%.

[0019] Furthermore, the coating agent is one or more of cellulose derivatives, polyvinyl compounds or sodium acrylate resins, etc., preferably Opadry gastric soluble coating agent.

[0020] Furthermore, the dry suspension may also contain a suspending agent and a flavoring agent.

[0021] Furthermore, the dry suspension comprises the following components in percentage by mass: compound SYN045 0.08%-0.7%, filler 83%-87%, binder 2.7%-3.4%, disintegrant 9.0%-11.2%, lubricant 0.9%-1.2%, suspending agent 0.39%-0.48% and flavoring agent 0.04%-0.06%.

[0022] Furthermore, the flavoring agent is one or more of citric acid, malic acid, aspartame or orange flavor, preferably orange flavor.

[0023] Furthermore, the suspending agent is one or more of xanthan gum, gum arabic, sodium alginate or chitosan, preferably xanthan gum.

[0024] The third object of the present invention is to provide a method for preparing the above-mentioned pharmaceutical composition comprising the compound SYN045, comprising the following steps: 1. Grinding and sieving the raw material SYN045, and sieving mannitol and hydroxypropyl cellulose separately for standby use; 2. Mixing the prescribed amount of SYN045 with half of the prescribed amount of mannitol, adding the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then adding the remaining prescribed amount of mannitol to mix to obtain a mixed powder; 3. Adding the mixed powder to a wet granulator, adding purified water, wet granulating, drying, and sieving to granulate; 4. Adding magnesium stearate to the granules obtained by wet granulation, mixing, and obtaining the total mixed granules, which is the pharmaceutical composition comprising the compound SYN045.

[0025] Furthermore, in the step 1, the raw material SYN045 is crushed and passed through an 80-mesh sieve, mannitol is passed through a 60-mesh sieve, and hydroxypropyl cellulose is passed through a 40-mesh sieve.

[0026] Furthermore, in the step 3, the granules are sieved through a 14-mesh sieve after drying.

[0027] Furthermore, in step 4, the mixing time is 3-15 min, preferably 10 min.

[0028] The fourth object of the present invention is to provide a second method for preparing the above-mentioned pharmaceutical composition comprising the compound SYN045, comprising the following steps: 1. Taking the prescribed amount of SYN045 and mannitol in an equal amount and adding them in a progressive manner, mixing them, adding corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, mixing them, and then sieving them to obtain a mixed powder; 2. Adding the mixed powder to a wet granulator and adding purified water, wet granulating them, and sieving and granulating them after drying; 3. Adding magnesium stearate to the granules obtained by wet granulation, mixing them, and obtaining the total mixed granules, which is the pharmaceutical composition comprising the compound SYN045.

[0029] Furthermore, in the step 1, corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose are added, mixed and then passed through a 60-mesh sieve.

[0030] Furthermore, in the step 2, the granules are sieved through a 14-mesh sieve after drying.

[0031] Furthermore, in step 3, the mixing time is 3-15 min, preferably 10 min.

[0032] The fifth object of the present invention is to provide a method for preparing ordinary tablets, coated tablets, capsules, granules and dry suspensions of the above-mentioned pharmaceutical composition comprising the compound SYN045, comprising the following steps: tableting the pharmaceutical composition comprising the compound SYN045, packaging, and obtaining SYN045 tablets; tableting the pharmaceutical composition comprising the compound SYN045, coating the obtained tablet cores, and packaging, and obtaining SYN045 coated tablets; filling the pharmaceutical composition comprising the compound SYN045 into capsules, packaging, and obtaining SYN045 capsules; filling the pharmaceutical composition comprising the compound SYN045 into granules, packaging, and obtaining SYN045 granules; adding a suspending agent and a flavoring agent to the pharmaceutical composition comprising the compound SYN045 according to the prescription amount, mixing, and filling and packaging the dry suspension, and obtaining a SYN045 dry suspension.

[0033] The new compound SYN045 is a poorly soluble drug. In the formulation screening study, it was found that mannitol is a very beneficial excipient for the dissolution of SYN045. However, in the formulation research, especially when the wet granulation process is used, there are obvious formulation stability problems, which easily produces impurities.

[0034] Combined with the preclinical rat efficacy dose confirmation experiment, it shows that SYN045 has a strong efficacy. The clinical experiment design is converted to 0.1 mg oral administration once a day for humans, indicating that the SYN045 preparation specifications are very small. The low dosage of active ingredients in the preparation makes it extremely difficult to mix evenly with the excipients in the prescription, resulting in the problem of low content uniformity of the preparation.

[0035] The inventor surprisingly found that by using a material mixed with mannitol and corn starch filler to evenly disperse SYN045, the material can have good fluidity, uniform content, rapid drug dissolution, and less impurities.

[0036] Through experimental investigation, by using a fixed ratio of mannitol and corn starch filler composition, the product quality problem of the wet process was solved, and a pharmaceutical composition containing SYN045 with excellent processing performance was obtained. The pharmaceutical composition was made into an oral solid preparation, and the SYN045 dissolution rate was fast and complete, and the dissolution rate of 20 minutes was above 90%, with good bioavailability. At the same time, the drug and excipients had good compatibility, the drug content of the preparation was high, the impurity content was low, the total impurity was less than 1.0%, and other single impurities were not higher than 0.1%. The product quality was good, ensuring the safety and effectiveness of clinical medication. At the same time, the content uniformity of the preparation product was high. This combination achieved the requirement of content uniformity without too complicated mixing methods, simplifying the preparation process.

[0037] The preparation process of the present invention can be mixed in an equal amount stepwise manner, which makes the mixing more uniform. Alternatively, the raw material drug and half of the mannitol are first mixed and then mixed with the remaining auxiliary materials. The latter can also meet the content uniformity requirements in the quality standard by optimizing the process, and the operation is simpler and faster, which is suitable for industrial production. DETAILED DESCRIPTION

[0038] The present invention is further described in detail below through specific implementation modes, but it is only used to help understand the present invention so that professionals in the field can implement or use the present invention, and does not constitute any limitation to the present invention.

[0039] Example 1

[0040] Preparation of SYN045 tablets (1000 tablets)

[0041] A SYN045 tablet comprising the following components in percentage by mass:

[0042]

[0043]

[0044] Preparation method:

[0045] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0046] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0047] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0048] 4. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0049] 5. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0050] Example 2

[0051] Preparation of SYN045 tablets (1000 tablets)

[0052] A SYN045 tablet comprising the following components in percentage by mass:

[0053]

[0054] Preparation method:

[0055] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0056] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0057] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0058] 4. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0059] 5. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0060] Example 3

[0061] Preparation of SYN045 tablets (1000 tablets)

[0062] A SYN045 tablet comprising the following components in percentage by mass:

[0063]

[0064] Preparation method:

[0065] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0066] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0067] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0068] 4. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0069] 5. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0070] Example 4

[0071] Preparation of SYN045 tablets (1000 tablets)

[0072] A SYN045 tablet comprising the following components in percentage by mass:

[0073]

[0074] Preparation method:

[0075] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0076] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0077] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0078] 4. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0079] 5. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0080] Example 5

[0081] Preparation of SYN045 tablets (1000 tablets)

[0082] A SYN045 tablet comprising the following components in percentage by mass:

[0083]

[0084] Preparation method:

[0085] 1. Take the prescribed amount of SYN045 and mannitol in equal amounts and mix them evenly. Add corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose and mix well. Pass through a 60-mesh sieve to obtain a mixed powder.

[0086] 2. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to size the particles.

[0087] 3. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0088] 4. The mixed granules are tableted and packaged to obtain SYN045 tablets.

[0089] Example 6

[0090] Preparation of SYN045 tablets (1000 tablets)

[0091] A SYN045 tablet comprising the following components in percentage by mass:

[0092]

[0093]

[0094] Preparation method:

[0095] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0096] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0097] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0098] 4. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0099] 5. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0100] Example 7

[0101] Preparation of SYN045 tablets (1000 tablets)

[0102] A SYN045 tablet comprising the following components in percentage by mass:

[0103]

[0104] Preparation method:

[0105] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0106] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0107] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0108] 4. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0109] 5. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0110] Example 8

[0111] Preparation of SYN045 tablets (1000 tablets)

[0112] A SYN045 tablet comprising the following components in percentage by mass:

[0113]

[0114] Preparation method:

[0115] 1. Take the prescribed amount of SYN045 and mannitol in equal amounts and mix them evenly. Add corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose and mix well. Pass through a 60-mesh sieve to obtain a mixed powder.

[0116] 2. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to size the particles.

[0117] 3. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0118] 4. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0119] Example 9

[0120] Preparation of SYN045 tablets (1000 tablets)

[0121] A SYN045 tablet comprising the following components in percentage by mass:

[0122]

[0123] Preparation method:

[0124] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0125] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0126] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0127] 4. Add talcum powder to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0128] 5. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0129] Example 10

[0130] Preparation of SYN045 capsules (1000 capsules)

[0131] A SYN045 capsule comprising the following components in percentage by mass:

[0132]

[0133]

[0134] Preparation method:

[0135] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0136] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0137] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0138] 4. Add talcum powder to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0139] 5. Fill the total mixed granules into capsules and package them to obtain SYN045 capsules.

[0140] Embodiment 11

[0141] Preparation of SYN045 granules (1000 bags)

[0142] A SYN045 granule, comprising the following components in percentage by mass:

[0143]

[0144] Preparation method:

[0145] 1. Take the prescribed amount of SYN045 and mannitol in equal amounts and mix them evenly. Add corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose and mix well. Pass through a 60-mesh sieve to obtain a mixed powder.

[0146] 2. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to size the particles.

[0147] 3. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0148] 4. Fill and package the total mixed granules to obtain SYN045 granules.

[0149] Example 12

[0150] Preparation of SYN045 tablets (1000 tablets)

[0151] A SYN045 tablet comprising the following components in percentage by mass:

[0152]

[0153] Preparation method:

[0154] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0155] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0156] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0157] 4. Add talcum powder to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0158] 5. The total mixed granules are tableted, and the obtained tablet cores are coated with Opadry gastric soluble coating powder and packaged to obtain SYN045 coated tablets.

[0159] Example 13

[0160] Preparation of SYN045 tablets (1000 tablets)

[0161] A SYN045 tablet comprising the following components in percentage by mass:

[0162]

[0163] Preparation method:

[0164] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0165] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0166] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0167] 4. Add talcum powder to the granules obtained by wet granulation and mix for 3 minutes to obtain the total mixed granules;

[0168] 5. The total mixed granules are tableted, and the obtained tablet cores are coated with Opadry gastric soluble coating powder and packaged to obtain SYN045 coated tablets.

[0169] Embodiment 14

[0170] Preparation of SYN045 tablets (1000 tablets)

[0171] A SYN045 tablet comprising the following components in percentage by mass:

[0172]

[0173] Preparation method:

[0174] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0175] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0176] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0177] 4. Add talcum powder to the granules obtained by wet granulation and mix for 15 minutes to obtain the total mixed granules;

[0178] 5. The total mixed granules are tableted, and the obtained tablet cores are coated with Opadry gastric soluble coating powder and packaged to obtain SYN045 coated tablets.

[0179] Embodiment 15

[0180] Preparation of SYN045 dry suspension (1000 bags)

[0181] A SYN045 dry suspension comprises the following components in percentage by weight:

[0182]

[0183]

[0184] Preparation method:

[0185] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0186] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0187] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0188] 4. Add magnesium stearate, xanthan gum and orange flavor to the granules obtained by wet granulation, mix for 10 minutes, and obtain the total mixed granules;

[0189] 5. Fill and package the total mixed granules into a dry suspension to obtain a SYN045 dry suspension.

[0190] Example 16

[0191] Preparation of SYN045 dry suspension (1000 bags)

[0192] A SYN045 dry suspension comprises the following components in percentage by weight:

[0193]

[0194]

[0195] Preparation method:

[0196] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0197] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0198] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0199] 4. Add magnesium stearate, xanthan gum and orange flavor to the granules obtained by wet granulation, mix for 10 minutes, and obtain the total mixed granules;

[0200] 5. Fill and package the total mixed granules into a dry suspension to obtain a SYN045 dry suspension.

[0201] Embodiment 17

[0202] Preparation of SYN045 dry suspension (1000 bags)

[0203] A SYN045 dry suspension comprises the following components in percentage by weight:

[0204]

[0205]

[0206] Preparation method:

[0207] 1. Grind the raw material SYN045 and pass it through an 80-mesh sieve, pass mannitol through a 60-mesh sieve, and pass hydroxypropyl cellulose through a 40-mesh sieve for later use;

[0208] 2. Take the prescribed amount of SYN045 and mix it with half of the prescribed amount of mannitol, add the prescribed amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescribed amount of mannitol and mix well to obtain a mixed powder;

[0209] 3. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to granulate;

[0210] 4. Add magnesium stearate, xanthan gum and orange flavor to the granules obtained by wet granulation, mix for 10 minutes, and obtain the total mixed granules;

[0211] 5. Fill and package the total mixed granules into a dry suspension to obtain a SYN045 dry suspension.

[0212] Comparative Example 1

[0213] Preparation of SYN045 tablets (1000 tablets)

[0214] A SYN045 tablet comprising the following components in percentage by mass:

[0215]

[0216] The preparation method is the same as that in Example 1, except that the amount of corn starch in Example 1 is increased, and the types and amounts of other raw materials and auxiliary materials are the same.

[0217] Comparative Example 2

[0218] Preparation of SYN045 tablets (1000 tablets)

[0219] A SYN045 tablet comprising the following components in percentage by mass:

[0220]

[0221] The preparation method is the same as that in Example 1, except that the amount of corn starch in Example 1 is reduced, and the types and amounts of other raw materials and auxiliary materials are the same.

[0222] Comparative Example 3

[0223] Preparation of SYN045 tablets (1000 tablets)

[0224] A SYN045 tablet comprising the following components in percentage by mass:

[0225]

[0226] The preparation method is the same as that in Example 1, except that the mannitol in Example 1 is replaced by lactose, and the types and amounts of other raw materials and auxiliary materials are the same.

[0227] Comparative Example 4

[0228] Preparation of SYN045 tablets (1000 tablets)

[0229] A SYN045 tablet comprising the following components in percentage by mass:

[0230]

[0231] The preparation method is the same as that in Example 1, except that the corn starch in Example 1 is replaced by potato starch, and the types and amounts of other raw materials and auxiliary materials are the same.

[0232] Comparative Example 5

[0233] Preparation of SYN045 tablets (1000 tablets)

[0234] A SYN045 tablet comprising the following components in percentage by mass:

[0235]

[0236] Preparation method:

[0237] 1. Take the prescribed amount of SYN045 and mix it with mannitol, corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose for 20 minutes to obtain a mixed powder;

[0238] 2. Add the mixed powder into the wet granulator and add purified water for wet granulation. After drying, pass through a 14-mesh sieve to size the particles.

[0239] 3. Add magnesium stearate to the granules obtained by wet granulation and mix for 10 minutes to obtain the total mixed granules;

[0240] 4. The total mixed granules are tableted and packaged to obtain SYN045 tablets.

[0241] Test Example 1 Quality Study

[0242] In order to examine the quality of the products, the quality of the samples prepared in Examples 1-17 and Comparative Examples 1-5 was compared. Samples were taken from each of the above products at 0 month to detect the content, related substances, content uniformity and dissolution. The results are shown in Table 1.

[0243] Content detection method:

[0244] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).

[0245] Solvent methanol-water (80:20)

[0246] Test solution Take 10 tablets of this product, put them in a 100ml volumetric bottle, add an appropriate amount of solvent, dissolve them by ultrasonic, then add solvent to dilute to the scale, shake well, and filter.

[0247] Reference solution Take an appropriate amount of SYN045 reference substance, weigh accurately, add solvent to dissolve by ultrasonication and quantitatively dilute to make a solution containing about 60 μg per 1 ml, and shake well. The preparation of the compound SYN045 reference substance refers to patent CN202410701022.4.

[0248] The chromatographic conditions were as follows: octadecylsilane bonded silica gel was used as filler; 0.2% (v / v) formic acid aqueous solution-methanol (20:80) was used as mobile phase; the flow rate was 1 ml per minute; the column temperature was 30° C.; the detection wavelength was 280 nm; and the injection volume was 20 μl.

[0249] Determination method: Accurately measure the test solution and the reference solution, inject them into the liquid chromatograph respectively, record the chromatogram, and calculate by peak area according to the external standard method.

[0250] Content uniformity test method:

[0251] Determined according to the content uniformity test method (General Rules 0941 of Part IV of the Chinese Pharmacopoeia 2020 Edition).

[0252] Take 1 tablet / capsule / bag of this product, place it in a 10ml volumetric bottle, add an appropriate amount of solvent (methanol-water 80:20), dissolve it by ultrasonication, then add solvent to dilute to the scale, shake well, filter, and use as the test solution.

[0253] Determine the content according to the method under the content determination item, and calculate the content uniformity of 10 tablets / capsules / bags, which should comply with the regulations (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0941). The content uniformity requirements are A+2.2S≤15.0, RSD<5%.

[0254] Related substance detection methods:

[0255] Determined according to high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).

[0256] Test solution Take an appropriate amount of the product or its contents, weigh accurately, add mobile phase to dissolve and quantitatively dilute to make a solution containing about 0.5 mg of compound SYN045 per 1 mL, filter, and take the filtrate.

[0257] Chromatographic conditions: Column: Welchrom-C 18 Chromatographic column (4.6mmx200mm, 5μm); mobile phase: 0.1mol / L sodium dihydrogen phosphate solution (pH adjusted to 4.0 with phosphoric acid)-acetonitrile (55:45); flow rate: 1.0mL / min; detection wavelength: 280nm; injection volume: 20μL.

[0258] Determination method: Accurately measure the test solution, inject it into the liquid chromatograph, and record the chromatogram.

[0259] If there are impurity peaks in the chromatogram of the limit test solution, the total amount of impurities calculated by the area normalization method shall not exceed 1.5%, the single largest impurity shall not exceed 0.5%, and the single other impurity shall not exceed 0.2%.

[0260] Dissolution test method:

[0261] It was determined according to the dissolution and release method (General Rules 0931 Method 2 of Part IV of the Chinese Pharmacopoeia 2020 Edition) and high performance liquid chromatography (General Rules 0512 of Part IV of the Chinese Pharmacopoeia 2020 Edition).

[0262] Use 900ml of pH1.0 hydrochloric acid solution containing 0.3% SDS as the dissolution medium, and the rotation speed is 50 revolutions per minute. Take samples after 5min, 10min, 15min, 20min, and 30min respectively. Take the test solution and the reference solution, and measure the content at a wavelength of 280nm. Calculate the dissolution rate of each tablet at different times, and the dissolution rate requirement is 20min>80%.

[0263] Table 1 Drug quality research test data

[0264]

[0265]

[0266] Test conclusion:

[0267] Through experimental research, it was found that the samples prepared in Examples 1-17 had high drug content and low impurity content, with total impurities less than 1.0%, other single impurities not higher than 0.1%, high solubility, and the solubility in 20 minutes was all above 90%, meeting the requirement of "dissolution in 20 minutes is greater than 80%", high content uniformity, and all met the requirements of "RSD%<5%, A+2.2S≤15.0", and small content difference.

[0268] Among them, Examples 5, 8, and 11 adopt an equal amount of progressive mixing method, and the content uniformity is relatively higher and the mixing is more uniform; while the remaining examples adopt a method of first mixing the API with half of the mannitol and then continuing to mix with the remaining excipients, and their content uniformity is generally slightly inferior to that of Examples 5, 8, and 11, but it is also sufficient to meet the requirements of the quality standards, and its operational convenience is further improved. Example 13 and Example 14 achieve the same effect as Example 12; Example 16 and Example 17 achieve the same effect as Example 15.

[0269] The amount of corn starch used in Comparative Example 1 is too high, resulting in a significant decrease in the solubility of the preparation product. The 20-min solubility is 79.6%, which is lower than the lower limit of 80% required by the solubility quality standard, and the product quality is difficult to guarantee.

[0270] The amount of corn starch used in Comparative Example 2 is too low, resulting in a decrease in the content of the preparation product, which is 97.7%. The impurities are significantly increased, with total impurities being 1.61%, exceeding 1.5%, and other single impurities being 0.17%. The product quality cannot be guaranteed.

[0271] In comparative example 3, the filler mannitol is replaced with lactose, and the content is reduced to 92.5%, and the impurities are increased. The total impurities are 1.88%, which is more than 1.5%, and the other single impurities are 0.19%. The product quality cannot be guaranteed. At the same time, the solubility is significantly reduced, and the 20min solubility is only 78.8%, which is lower than the lower limit of 80% required by the quality standard, and the quality is difficult to guarantee.

[0272] In Comparative Example 4, the filler corn starch was replaced with potato starch, and the content of the preparation was significantly reduced to only 90.1%, and the impurities increased significantly. The total impurities were 1.99%, which exceeded 1.5%, and the other single impurities were 0.20%. There were serious problems with the quality of the drug.

[0273] Comparative Example 5 is a preparation process in which the raw and auxiliary materials are directly mixed without equal addition and screening operations. The content uniformity is significantly reduced, A+2.2S is 19.7, and RSD is 7.2%, which does not meet the quality standard requirements of "RSD% <5%, A+2.2S ≤15.0", and the product quality cannot be guaranteed.

[0274] In summary, the preparation product prepared by the composition of the present invention has high content, few impurities, high dissolution, and high content uniformity, with total impurities less than 1.0%, other single impurities not higher than 0.1%, high dissolution, and the dissolution rate of 20 minutes is above 90%, which meets the requirement of "20 minutes dissolution rate is greater than 80%" in the quality standard, improves bioavailability, ensures the safety and effectiveness of clinical medication, and greatly improves product quality. In addition, the optimized preparation process is simple to operate, which also ensures product quality and is conducive to industrial production and application.

[0275] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A pharmaceutical composition comprising compound SYN045, It is characterized in that The invention comprises the following components in percentage by weight: 0.06%-0.8% of compound SYN045, 83%-88% of filler, 2.7%-3.4% of binder, 9.0%-11.2% of disintegrant and 0.9%-1.2% of lubricant; Wherein, the filler is a mixture of mannitol and corn starch; The mass ratio of the mannitol to corn starch is 14:90-125.

2. The pharmaceutical composition comprising compound SYN045 as claimed in claim 1, It is characterized in that The binder is hydroxypropyl cellulose; and / or The disintegrant is low-substituted hydroxypropyl cellulose; and / or The lubricant is one or both of magnesium stearate and talc.

3. A pharmaceutical preparation, It is characterized in that A pharmaceutical composition comprising the compound SYN045 as described in claim 1 or 2.

4. The pharmaceutical preparation according to claim 3, It is characterized in that The dosage form of the pharmaceutical preparation is tablet, capsule, granule or dry suspension.

5. The pharmaceutical preparation according to claim 4, It is characterized in that The tablet comprises the following components in percentage by mass: 0.08%-0.7% of compound SYN045, 81%-85% of filler, 2.6%-3.3% of binder, 8.8%-10.9% of disintegrant, 0.88%-1.09% of lubricant and 2.6%-3.3% of coating agent.

6. The pharmaceutical preparation according to claim 5, It is characterized in that The coating agent is one or more of cellulose derivatives, polyvinyl compounds or sodium acrylate resins, etc.; and / or The binder is hydroxypropyl cellulose; and / or The disintegrant is low-substituted hydroxypropyl cellulose; and / or The lubricant is one or both of magnesium stearate and talc.

7. The pharmaceutical preparation according to claim 4, It is characterized in that The dry suspension comprises the following components in percentage by mass: 0.08%-0.7% of compound SYN045, 83%-87% of filler, 2.7%-3.4% of binder, 9.0%-11.2% of disintegrant, 0.9%-1.2% of lubricant, 0.39%-0.48% of suspending agent and 0.04%-0.06% of flavoring agent.

8. The pharmaceutical preparation according to claim 7, It is characterized in that The suspending agent is one or more of xanthan gum, gum arabic, sodium alginate or chitosan; and / or The binder is hydroxypropyl cellulose; and / or The disintegrant is low-substituted hydroxypropyl cellulose; and / or The lubricant is one or both of magnesium stearate and talc.

9. A method for preparing a pharmaceutical composition comprising compound SYN045 according to any one of claims 1 to 2, It is characterized in that The following steps are involved: S1. Crush and sieve the raw material SYN045, and sieve mannitol and hydroxypropyl cellulose separately for later use; S2, take the prescription amount of SYN045 and half of the prescription amount of mannitol and mix them evenly, add the prescription amount of corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose, and then add the remaining prescription amount of mannitol and mix them evenly to obtain a mixed powder; S3, adding the mixed powder to the prescribed amount of purified water, performing wet granulation, drying, sieving and granulating to obtain prefabricated granules; S4. Add magnesium stearate to the prefabricated granules and mix well to obtain a pharmaceutical composition comprising the compound SYN045.

10. A method for preparing a pharmaceutical composition comprising compound SYN045 according to any one of claims 1 to 2, It is characterized in that The following steps are involved: S1. Take the prescribed amount of SYN045 and mannitol in equal amounts and mix them evenly, add corn starch, low-substituted hydroxypropyl cellulose and hydroxypropyl cellulose and continue to mix evenly, sieve to obtain a mixed powder; S2, adding the mixed powder to the prescribed amount of purified water, performing wet granulation, drying, sieving and granulating to obtain prefabricated granules; S3. Add magnesium stearate to the preformed granules and mix well to obtain a pharmaceutical composition comprising the compound SYN045.

Citation Information

Patent Citations

  • Acrylic acid endothelin receptor antagonist as well as preparation method and application thereof

    CN102093286A

  • Heterocyclic derivatives and medicines

    CN1516690A

  • New 2-(1,3,5-triazin-2-yloxy)-3,3-diaryl-propionic acid derivatives, are selective ET-A receptor antagonists useful e.g. for treating cardiac insufficiency, hypertension, liver cirrhosis, prostate cancer or pancreatitis

    DE10004052A1